ACD857

ACD857 is a small molecule drug candidate developed by AlzeCure Pharma within its NeuroRestore platform. It is designed as a symptom-relieving therapy for diseases characterized by cognitive impairment, with Alzheimer's disease as the primary indication. The mechanism of action involves positive allosteric modulation of the TrkA receptor (nerve growth factor receptor), enhancing neurotrophin signaling—specifically nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). This enhancement aims to improve neuronal function, synaptic plasticity, and cognition while potentially providing neuroprotective and disease-modifying effects. As of June 2025, ACD857 remains in preclinical development[1][2][3][4].